We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Adaptimmune Therapeutics PLC | NASDAQ:ADAP | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.83% | 1.22 | 1.18 | 1.22 | 1.25 | 1.17 | 1.25 | 716,618 | 00:26:10 |
“We have seen impressive clinical results with our first-generation product, afami-cel, in sarcoma, and we set a goal to increase potency to achieve responses in additional indications,” said Elliot Norry, Adaptimmune’s Chief Medical Officer. “To that end, we delivered our first next-gen product into the clinic incorporating CD8 and have shown responses across a broad range of solid tumor types in our SURPASS program. We have now presented preclinical data at ASGCT from our second next-gen therapy designed to improve durability and persistence of SPEAR T-cells that supports clinical investigation.”
New next-generation SPEAR T-cells show potential for enhanced clinical activity with improved proliferation, survival, and infiltration of immune cells into tumors in preclinical studies
TILs engineered to produce IL-7 may result in a more effective therapy for people with metastatic melanoma with preclinical data demonstrating enhanced TIL survival
The Company will also present a poster entitled “A Novel Flow Cytometry Method for Rapid Assessment of Lentiviral Detection” on May 19th.
About AdaptimmuneAdaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2021, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Corporate Affairs and CommunicationsT: +44 1235 430 583M: +44 7718 453 176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — VP, Investor RelationsT: +1 215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
_______________1 PRIME technology used in collaboration with Noile-Immune Biotech 2 Hulen TM, et al. Immuno. 2021;1(3):194; Muul LM, et al. J Immunol. 1987;138(3):989
1 Year Adaptimmune Therapeutics Chart |
1 Month Adaptimmune Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions